C-erb-b2 expression in luminal b breast cancer has higher axillary lymph node involvement ratio

Basit Öğe Kaydı
dc.contributor.authorDegirmencioglu, Gurkan
dc.contributor.authorKafadar, Mehmet Tolga
dc.contributor.authorKilic, Mehmet
dc.date.accessioned2024-04-24T17:24:38Z
dc.date.available2024-04-24T17:24:38Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: In this study, the effect of c-erb-B-2 (HER-2/neu) expression on axillary lymph node involvement in Luminal-B breast cancer was examined. Material and Methods: One hundred seven female patients were included in this study who were classified as Stage 1, Stage 2 and Stage 3 pathologically, with positive Estrogen (ER) and Progesterone Receptor (PR) and with the diagnosis of invasive ductal carcinoma with a single focal mass and not a synchronous tumour and received surgical therapy. The lymph node involvement ratio (LNIR) was divided into two groups as over and below 25%. These acquired data were compared with the groups with positive and negative c-erbB-2 gene expression, axillary LNI status, and LNIR separately. Results: The data of 107 female patients aged between 27 and 87 years were evaluated in this study. The mean age of the patients was 55.69 +/- 12.68 years. LNIR was found to be less than 25% in 76.6% (n: 82) of the patients, and over 25% in 23.4% (n: 25) of the patients. The c-erbB-2 positivity was significantly different in the axilla with and without metastatic lymphadenopathy (p =0.026). There was no statistically significant relationship between tumour diameter and metastatic lymphadenopathy. Although axillary metastatic lymphadenopathy positivity was found to be significant in patients with lymphovascular invasion (p<0.001), it was also found to be significant, as in the group with LNIR>25 (p<0.001). Discussion: This study demonstrated that high expression of c-erbB-2 is associated with poor prognosis of breast cancer by increasing axillary LNI. In hormone (Estrogen and Progesterone) positive patients, if c-erB-2 is also positive, there is greater number of axillary LNI.en_US
dc.identifier.doi10.4328/ACAM.21121
dc.identifier.endpage849en_US
dc.identifier.issn2667-663X
dc.identifier.issue8en_US
dc.identifier.startpage845en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.21121
dc.identifier.urihttps://hdl.handle.net/11468/19768
dc.identifier.volume13en_US
dc.identifier.wosWOS:000852590900004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInvolvementen_US
dc.subjectAxillary Lymph Nodeen_US
dc.subjectBreast Canceren_US
dc.titleC-erb-b2 expression in luminal b breast cancer has higher axillary lymph node involvement ratioen_US
dc.titleC-erb-b2 expression in luminal b breast cancer has higher axillary lymph node involvement ratio
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu